Detail akcie Theralase Tech Inc online

Business Summary: Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Theralase Technologies Inc revenues decreased 6% to C$1.1M. Net loss decreased 13% to C$4.6M. Revenues reflect Canada segment decrease of 17% to C$840K, International segment decrease of 91% to C$2K. Lower net loss reflects R & d decrease of 36% to C$2.5M (expense), (Gain) loss on foreign exchange decrease from C$28K (expense) to C$4K (income).